Exploring the interplay between psychedelics and stimulants like Adderall and Vyvanse offers a fresh perspective on ADHD treatment, highlighting alternatives that tap into enhanced focus and cognitive flexibility.
This article delves into the potential of psychedelics to complement traditional ADHD therapies, underscoring the need for a nuanced understanding of their effects on mental health and behavior management.
Attention-Deficit/Hyperactivity Disorder (ADHD) significantly impacts the quality of life for millions of individuals worldwide, spanning across all ages. The conventional treatment paradigm has predominantly relied on psychostimulants, such as amphetamines and methylphenidate, which target the central nervous system to enhance focus, reduce fatigue, and modulate behavior.
However, the chronic use of these medications brings forth a plethora of challenges, including the risk of habit formation, dependency, and a range of adverse psychological and physiological effects. Simultaneously, the resurgence of interest in the therapeutic potential of psychedelics for various psychiatric conditions has paved the way for innovative treatment approaches.
Psychedelics, known for their profound effects on consciousness and perception, may offer alternative or adjunctive benefits in managing ADHD symptoms, particularly for those who are seeking broader symptom management strategies, have experienced significant side effects, or have developed a tolerance to conventional stimulants.
This review meticulously explores the biochemical mechanisms, therapeutic potentials, and the intricate interplay between psychostimulants and psychedelics in the context of ADHD management.
By examining current research, clinical trials, and pharmacological interactions, this article aims to elucidate the potential synergies and challenges of integrating psychedelics into ADHD treatment regimes, highlighting the necessity for a nuanced understanding of these substances in psychiatric care.
Download Our Free Psilocybin Sourcing Guide
For harm-reduction purposes, we provide links to online psilocybin vendors, local stores, delivery services, and spore vendors for growing your own medicine at home.
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity. The condition’s complexity and the diversity in symptom presentation necessitate a multifaceted approach to treatment and management.
Traditionally, ADHD has been managed with psychostimulant medications, which are considered the gold standard due to their efficacy in improving concentration and enhancing overall cognitive function.
These medications operate by augmenting the levels of central nervous system neurotransmitters, notably dopamine and norepinephrine, thus directly impacting arousal and attention mechanisms.
Despite their efficacy, the reliance on psychostimulants is fraught with challenges. The potential for abuse, dependency, and a broad spectrum of side effects, from sleep disturbances to cardiovascular risks, underscores the need for alternative treatments.
In this context, the exploration of psychedelics—substances historically associated with counterculture and recreational use—has emerged as a frontier in psychiatric research.
Recent studies have revisited the therapeutic potential of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and 3,4-methylenedioxymethamphetamine (MDMA), for a range of psychiatric conditions, including depression, post-traumatic stress disorder (PTSD), and now, ADHD.
The mechanisms through which psychedelics exert their effects are distinct from those of traditional stimulants, often involving serotonin receptor modulation, which can lead to altered states of consciousness and significant shifts in perception, mood, and cognition.
Given these properties, psychedelics could potentially address some of the underlying issues in ADHD, such as impaired executive function, emotional dysregulation, and novelty seeking.
However, the combination of psychedelics with stimulants raises complex pharmacological and safety considerations, given their overlapping yet distinct mechanisms of action.
Recommended Reading: Can You Mix Psychedelic Mushrooms With Adderall & Stimulants?
This comprehensive review delves into the pharmacology of both psychostimulants and psychedelics, their potential roles in ADHD management, and the critical considerations arising from their combined use.
Psychostimulants: Mechanisms and Effects
| Class | Name |
| Amphetamine |
|
| Methylphenidate |
|
| Other |
|
Psychostimulants, encompassing a broad class of medications such as amphetamines (Adderall, Vyvanse, Dexedrine) and methylphenidate (Ritalin, Concerta, Focalin), play a pivotal role in the management of Attention-Deficit/Hyperactivity Disorder (ADHD) and other conditions characterized by deficits in attention, control of impulsivity, and hyperactivity.
The primary mechanism through which these drugs exert their therapeutic effects is by stimulating the central nervous system (CNS), with a particular focus on enhancing neurotransmission of dopamine and norepinephrine. These neurotransmitters are crucial for regulating attention, arousal, and executive functions, which are often compromised in individuals with ADHD.
Dopamine, a neurotransmitter associated with reward and motivation systems in the brain, plays a significant role in the regulation of attention and executive functions. By increasing the availability of dopamine in the synaptic cleft, psychostimulants improve the ability of individuals with ADHD to focus on tasks, reduce impulsivity, and enhance overall cognitive function.
“How ADHD Medication Works” by Julie Rawe
Norepinephrine, on the other hand, is involved in regulating arousal, alertness, and mood. The augmentation of norepinephrine activity by psychostimulants contributes to increased wakefulness, attention, and responsiveness to stimuli, further supporting their utility in managing ADHD symptoms.
The elevation in mood and energy levels observed in individuals taking psychostimulants is another noteworthy effect, often leading to improved academic and occupational performance, better social interactions, and an overall enhancement in quality of life.
However, the profound impact of these medications on the CNS and their potential to significantly alter neurotransmitter levels bring about considerations regarding their long-term use and safety profile.
Despite the clear therapeutic benefits, psychostimulants are not devoid of drawbacks. The potential for abuse and addiction is a significant concern, attributed to their mechanism of action on the brain’s reward pathway.
This risk necessitates a careful and individualized approach to prescribing these medications, ensuring that they are used in a manner that maximizes their benefits while minimizing the potential for dependence and other adverse effects.
Monitoring for signs of misuse, adjusting doses as necessary, and considering alternative or adjunctive treatments when appropriate are critical components of responsible psychostimulant management.
Furthermore, side effects such as insomnia, decreased appetite, emotional “flatness”, and cardiovascular changes require ongoing attention and management to ensure the safe and effective use of these powerful medications in treating ADHD and related conditions.
Psychedelics: Mechanisms and Potential in ADHD
Psychedelics represent a diverse class of substances including MDMA (3,4-methylenedioxymethamphetamine), LSD (lysergic acid diethylamide), and psilocybin, which is derived from certain species of mushrooms.
Unlike traditional stimulants that primarily enhance dopamine and norepinephrine neurotransmission to improve focus and energy, psychedelics operate through a significantly different mechanism, mainly influencing the serotonergic system.
This interaction with serotonin receptors, particularly the 5-HT2A receptor, is believed to be responsible for their unique effects on consciousness, perception, and mood.
The potential of psychedelics to induce profound alterations in consciousness and perception opens up novel therapeutic avenues for ADHD, a condition traditionally characterized by difficulties in maintaining attention, hyperactivity, and impulsive behavior.
The core of psychedelic therapy’s promise lies in its ability to enhance cognitive flexibility, allowing individuals to break free from rigid patterns of thought and behavior. This flexibility could be particularly beneficial in ADHD, enabling sufferers to adopt more adaptive strategies for attention and action regulation.
Moreover, psychedelics have shown potential in improving emotional regulation, a crucial aspect considering the emotional dysregulation often observed in individuals with ADHD. By facilitating a more profound connection with emotions and improving the processing of emotional experiences, psychedelics could help address the emotional impulsivity component of ADHD.
Comment
byu/NeuronsToNirvana from discussion
inscience
This emotional aspect is pivotal because traditional ADHD treatments often focus predominantly on cognitive symptoms, leaving emotional regulation relatively unaddressed. Another intriguing aspect of psychedelics is their empathogenic properties, particularly evident in substances like MDMA.
Psychedelics’ empathogenic properties can foster a heightened sense of connection and empathy, which may counteract the social difficulties experienced by individuals with ADHD. Enhancing social connectivity and emotional understanding can play a significant role in the holistic management of ADHD, beyond the mere mitigation of attention deficits.
Comment
byu/NeuronsToNirvana from discussion
inscience
MDMA, a psychedelic phenethylamine, which embodies both stimulant and psychedelic characteristics, offers an exciting area of exploration for ADHD management. Its ability to impact the serotonergic system while also exhibiting stimulant-like effects presents a unique dual-action potential.
This could theoretically provide the attention-enhancing benefits of stimulants alongside the cognitive and emotional regulatory advantages of psychedelics, all the while minimizing the risk of addiction associated with traditional stimulant medications.
The therapeutic application of psychedelics in ADHD, however, is not without its challenges and considerations. The profound experiences induced by these substances often necessitate a carefully structured therapeutic setting, alongside professional guidance to navigate the altered states of consciousness safely and productively.
Additionally, the optimal dosing strategies of psychedelics for ADHD treatment are areas that require further research.
Recommended Reading: Should I Microdose or Macrodose for My Psychedelic Experience?
Clinical trials and empirical studies focusing on psychedelics’ efficacy, safety, and mechanisms of action in the context of ADHD are essential to fully understand their therapeutic potential.
Rethinking ADHD: Misdiagnosis and the Potential of Psychedelic Therapy
One aspect that merits attention is the proposition that many instances diagnosed as ADHD could, in fact, represent misdiagnosed conditioned trauma responses from childhood. Evidence suggests that symptoms associated with ADHD can emerge following traumatic events in children’s lives.
Studies have found a significant and robust connection between experiences of abuse/neglect during childhood and the diagnosis of ADHD, persisting into young adulthood. Scenarios exist where if a mother undergoes considerable emotional stress during pregnancy, or if a child faces abuse or other forms of trauma early in life, their “inner emergency alarm” might stay activated throughout development.
As a result, such a child may exhibit typical ADHD symptoms, like inattentiveness, irritability, overreactivity to challenges, or even reactive aggression, which are actually manifestations of a chronic trauma response, not ADHD.
This distinction is vital because psychedelics, which have also shown promise in treating trauma symptoms, could be beneficial for individuals misdiagnosed with ADHD, suggesting that what appears as ADHD could, in reality, be a trauma response, making psychedelics a viable treatment option.
This phenomenon is not uncommon considering that studies have indicated that approximately 20 percent – or 900,000 – of the 4.5 million children currently identified as having ADHD likely have been misdiagnosed.
Furthermore, the process itself of evaluating stimulant treatment and considering psychedelic therapy can prompt a reevaluation of one’s ADHD diagnosis. Through assessing the diagnosis of ADHD and its impact on their lives, individuals might gain deeper insights into their condition, even revealing instances of misdiagnosis.
It may not even be that trauma underlies their symptoms; sometimes, the psychedelic experience itself can illuminate for someone previously diagnosed with ADHD that their challenge is not necessarily one of focus and inattention but rather of discipline.
It may also highlight signs of stimulant abuse, such as escalating doses, using stimulants for non-prescribed purposes, and experiencing negative consequences like social, occupational, or legal problems.
If stimulant abuse is identified, it’s important to address it promptly and effectively. In cases where individuals initially seek psychedelic use for ADHD treatment but discover underlying stimulant abuse patterns, transitioning to psychedelic-assisted therapy can be a viable option.
Interactions Between Stimulants and Psychedelics
The interplay between stimulants and psychedelics is a topic of considerable interest. Stimulants are commonly prescribed for conditions such as ADHD, enhancing focus and energy by increasing dopamine and norepinephrine levels in the brain.
Conversely, psychedelics like MDMA, LSD, and psilocybin, primarily affect the serotonergic system, altering consciousness, perception, and mood. When these two classes of drugs are combined, the resultant interactions can be unpredictable, leading to increased risks both psychologically and physiologically.
One of the most notable concerns with combining stimulants and psychedelics is the potential for exacerbated cardiovascular risks. Stimulants increase heart rate and blood pressure, effects that can be compounded by psychedelics, especially those with a stimulant component like MDMA. This combination can lead to an elevated risk of hypertensive crises, arrhythmias, and other cardiovascular events.
Comment
byu/coreyg129 from discussion
inadderall
Psychologically, the combination of stimulants and psychedelics can lead to an intensified experience that may not always be beneficial or desired. For instance, stimulants can enhance focus and alertness, while psychedelics can dissolve the ego and expand consciousness. This juxtaposition can lead to confusion, dysphoria, and anxiety.
“Don’t do it. The body load from the addy is gonna make you very very anxious, and the thought loops will be intensified.” – Reddit User
To better understand this juxtaposition, acknowledge how the ego serves as the thread that weaves our sense of self, grounding us in our personal identity and narrative. It is the “I” in our thoughts, emotions, and perceptions, providing a center from which we navigate the world.
Focus, on the other hand, acts as the lens through which our mental spotlight illuminates the objects of our attention.
Ego dissolution, a phenomenon often associated with the use of psychedelics, represents a profound unraveling of this thread, a temporary dissolving of the boundaries that define the self.
In this state, the distinction between the observer and the observed begins to blur, and the narrative that strings together past, present, and future fades into a broader, boundless experience of the moment. This dissolution can lead to a profound sense of unity and interconnectedness with all things, a merging with the infinite tapestry of existence beyond the confines of the individual self.
This expansive state stands in stark contrast to the concentrated beam of focus. Where focus narrows, ego dissolution broadens.
Regardless of psychedelics’ ego-dissolving properties, generally speaking, psychedelics tend to produce stimulating subjective effects, particularly LSD and MDMA. Combining psychedelics with stimulants often causes anxiety and overstimulation.
Comment
byu/CAT_JESUS from discussion
inLSD
A study involving the combination of methylphenidate and MDMA has highlighted these issues, showing that such combinations do not necessarily produce enhanced psychoactive benefits and may, in fact, increase the profile of adverse effects.
“The haemodynamic and adverse effects of co-administration of methylphenidate and MDMA were significantly higher compared with MDMA or methylphenidate alone.”
The pharmacodynamic interactions of MDMA and psychostimulants, such as the overlapping NET (norepinephrine transporter) and DAT (dopamine transporter) occupancy seen in the combination of methylphenidate and MDMA, can lead to complex effects.
“MDMA and methylphenidate levels and half-lives were unaffected by co-administration; however, researchers found that methylphenidate delayed the time it took for MDMA to reach maximum concentration. The researchers remark this may be due to methylphenidate reducing the absorption of MDMA.” (Sarparast et al. 2022)
Additionally, this mix caused an increase in adrenaline levels, heart rate, and blood pressure, and it reduced the usual positive feelings MDMA provides, leading to more complaints and side effects from those taking both drugs.
This combination also led to increased circulating epinephrine (adrenaline levels), heart rate, and blood pressure, and it reduced the usual positive feelings MDMA provides, leading to more complaints and side effects from those taking both drugs.
Given these findings, the integration of stimulants and psychedelics in therapeutic contexts must be approached with caution. Most clinical trials involving psychedelics exhibit exclusion criteria that do not allow stimulant use within at least five half-lives of the psychedelic session, which equates to approximately 72 hours for ADHD prescription stimulants.
“Current use of tricyclic antidepressants, serotonin reuptake inhibitors, antipsychotics, atypical antipsychotics, monoamine oxidase inhibitors (MAOIs), mood stabilizers (lithium), buspirone, mirtazapine, trazodone, or other drugs that modulate the serotonin system.
For individuals who have intermittent or PRN use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose.” – Rael Cahn, University of Southern California
“Participants were required to comply with lifestyle modifications, including a medically supervised discontinuation of psychiatric medications for a minimum of five half-lives plus one additional week before the baseline assessments.” (Mitchel et al., 2021)
In conclusion, while the combination of stimulants and psychedelics may hold some theoretical appeal for enhancing certain therapeutic outcomes, the potential for increased cardiovascular and psychological risks necessitates a careful and informed approach.
Find Confidence and Clarity with Psychedelic Passage’s Guidance
Hi there! We sincerely hope that you’ve found valuable takeaways that resonate with your current intentions. To explore research-based education, stay updated with psychedelic news, and benefit from practical how-to articles, we encourage you to head over to our resources page.
If you’re seeking personalized advice and are prepared to take the first step toward a therapeutic psychedelic experience, we invite you to book a consultation with our team of experienced psychedelic concierges.
This consultation is more than just a conversation; it’s an opportunity to be matched with a trustworthy local facilitator. You’ll be seamlessly connected to our rigorously vetted network of psychedelic guides, ensuring potential matches align with your needs.
Psychedelic Passage offers confidence and peace of mind by alleviating the burden of having to guess who’s right for you. If you want to discover how Psychedelic Passage can help you, we empower you to learn more about our services and check out client testimonials from those who’ve gone before you.
Your healing path is uniquely yours, and our commitment is to serve you at every juncture. Psychedelic Passage: Your Psychedelic Concierge — The easy, legal way to find trustworthy psilocybin guides, facilitators and psychedelic-assisted therapy near you in the United States.
Learn More About Our Network
Connect with Psychedelic Passage
-
- Listen to our podcast on Spotify, Apple Podcasts, and iHeartRadio
- Subscribe to our Youtube Channel
- Follow us on Instagram, Reddit, and Linked in for bite-sized updates and content.
References
-
- National Institutes of Health (NIH). (2008). Psychedelics and cognitive flexibility: An fMRI study. PMC. PMC2518387.
- National Institutes of Health (NIH). (2000). Effects of Psilocybin on time perception and temporal control of behaviour in humans. PMC. PMC10601982.
- National Institutes of Health (NIH). (2013). Serotonergic psychedelics and personality: A systematic review of contemporary research. PMC. PMC3666055.
- National Institutes of Health (NIH). (2014). Neural correlates of the LSD experience revealed by multimodal neuroimaging. PMC. PMC4147667.
-
Author links open overlay panelMesud Sarmanlu a b, a, b, c, d, e, … AbstractThe application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical. (2023). MDMA-Assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy. Retrieved from https://www.sciencedirect.com/science/article/pii/S027858462300129X
-
Cohen, I. V., Makunts, T., Atayee, R., & Abagyan, R. (2017). Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431207/
- National Institutes of Health (NIH). (2022). Exploring the therapeutic potential of microdosing psychedelics in depression. PMC. PMC9145110.
- Kuypers, K. P. C., et al. (2021). Psychedelic microdosing benefits and challenges: An empirical codebook. Nature. https://doi.org/10.1038/s41398-021-01706-y
- Erritzoe, D., et al. (n.d.). Psychedelics and mental health: A population study. Springer. https://doi.org/10.1007/s00213-020-05548-2
- National Institutes of Health (NIH). (2001). MDMA (“Ecstasy”): A review of its possible persistent psychological effects. PMC. PMC10716812.
- National Institutes of Health (NIH). (2022). Therapeutic potential of ayahuasca in grief: a prospective, observational study. PMC. PMC9177763.
-
Malcolm, B. (2024, February 17). Stimulants and psychedelics: Focus and surrender [Online webinar].
-
Carhart-Harris, R. L., et al. (2021). Trial of psilocybin versus escitalopram for depression. Nature Medicine. https://doi.org/10.1038/s41591-021-01336-3
